Dysbiosis of the Gut Microbiome in Lung CancerOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This case-control study asked whether the gut microbiome is altered in lung cancer, a question less explored than the lung microbiome. Researchers compared stool from patients and matched healthy controls. They sequenced the V3-V4 region of the 16S rRNA gene on the Illumina MiSeq platform. Analyses covered alpha diversity, beta diversity, and LEfSe biomarker detection. PICRUSt-style 16S function prediction estimated microbial metabolic pathway abundance between the two groups.
Who was studied?
The study enrolled 30 lung cancer patients (median age 61) and 30 matched healthy controls at a hospital in Harbin, China. None had taken medications in the 3 months before sampling. Among patients, 76.7 percent had non-small-cell lung cancer and 23.3 percent had small-cell lung cancer. Most were stage IIIA or IIIB by TNM classification. All samples were human stool, frozen in liquid nitrogen immediately after collection and stored at minus 80 degrees Celsius.
What were the most important findings?
Alpha diversity did not differ between groups (Shannon 3.28 controls versus 3.09 patients), but beta diversity composition differed significantly across taxonomic levels. LEfSe found 47 differentiated clades, 33 increased and 14 decreased in patients. The Actinobacteria phylum fell from 7.7 to 3.1 percent in patients (p = 0.041). Bifidobacterium dropped from 4.7 to 1.5 percent (p = 0.012). Enterococcus rose from 0.2 to 4.3 percent in patients (p = 0.019). Predicted microbial metabolic functions were broadly reduced in lung cancer.
What are the greatest implications of this study?
The findings support a lung-cancer-associated gut microbial signature, with reduced Bifidobacterium and Actinobacteria and elevated Enterococcus as candidate biomarkers. This points to the gut-microbiota-lung axis as a research and intervention target. Reduced predicted metabolic function suggests dysbiosis may impair beneficial microbial activity during disease. The design is cross-sectional with only 30 patients, so it cannot show causation. Viruses and mycoplasma were not captured by bacterial primers, a stated limitation.